SCHEMBL8415214

SCHEMBL8415214

CN(CCCN)CCCNC(=O)c1cccc2nc3ccccc3nc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 3/20 0.56
SMARCA2 P51531 1/20 0.52
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
SIGMAR1 Q99720 4/20 0.47
TMEM97 Q5BJF2 2/20 0.47
OPRM1 P35372 1/20 0.47
OPRK1 P41145 1/20 0.47
HTT P42858 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
MAPT P10636 2/20 0.46
AOX1 Q06278 1/20 0.45
TP53 P04637 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7566429 0.94 RAD52 (0.60) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL7997888 0.90 RAD52 (0.56) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL14440618 0.89 HDAC1 (0.61) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL8415106 0.88 RAD52 (0.55) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL8413271 0.86 RAD52 (0.57) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL7567201 0.85 RAD52 (0.57) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL7567106 0.85 RAD52 (0.77) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL7565910 0.85 RAD52 (0.55) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL7566551 0.84 RAD52 (0.53) RAD52SMARCA2HDAC1HDAC6SIGMAR1
SCHEMBL7568883 0.84 RAD52 (0.53) RAD52SMARCA2HDAC1HDAC6SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2007-08-16 US disclosed
EP-0934278-A1 BIS(ACRIDINECARBOXAMIDE) AND BIS(PHENAZINECARBOXAMIDE) AS ANTITUMOUR AGENTS XENOVA LIMITED (GB) 1999-08-11 EP disclosed
WO-1998017650-A1 BIS(ACRIDINECARBOXAMIDE) AND BIS(PHENAZINECARBOXAMIDE) AS ANTITUMOUR AGENTS XENOVA LIMITED (GB) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191372-A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy HIF1AN, HIF1A, HYOU1 RAD52 144/4885SMARCA2 2126/4885HDAC1 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.